Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori (Q44371256)

2 December 2017

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori (English)

1 reference

2 December 2017

1 reference

1 reference

T Furuta

1

1 reference

2 December 2017

N Shirai

2

1 reference

2 December 2017

M Kodaira

3

1 reference

2 December 2017

M Sugimoto

4

1 reference

2 December 2017

A Nogaki

5

1 reference

2 December 2017

S Kuriyama

6

1 reference

2 December 2017

M Iwaizumi

7

1 reference

2 December 2017

M Yamade

8

1 reference

2 December 2017

I Terakawa

9

1 reference

2 December 2017

K Ohashi

10

1 reference

2 December 2017

T Ishizaki

11

1 reference

2 December 2017

A Hishida

12

1 reference

2 December 2017

language of work or name

English

0 references

publication date

10 January 2007

1 reference

2 December 2017

8

1 reference

Clinical Pharmacology & Therapeutics

inferred from page(s)

published in

1 reference

2 December 2017

81

1 reference

2 December 2017

4

1 reference

2 December 2017

521-528

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100043

2 December 2017

0 references

cites work

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Helicobacter pyloriInfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

Helicobacter pylori infection and gastric lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100043

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100043

1 reference

Dimensions Publication ID

2 December 2017

0 references

1 reference